Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024
27 Março 2024 - 9:30AM
Business Wire
Omeros Corporation (NASDAQ: OMER), today announced that the
company will issue its financial results for the quarter and year
ended December 31, 2023, on Monday, April 1, 2024, after the market
closes. Omeros management will host a conference call and webcast
that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to
discuss the financial results as well as recent developments and
highlights.
Conference Call Details
For online access to the live webcast of the conference call, go
to Omeros’ website at
https://investor.omeros.com/upcoming-events.
To access the live conference call via phone, participants must
register at this link to receive a unique PIN. Once registered, you
will have two options: (1) Dial in to the conference line provided
at the registration site using the PIN provided to you, or (2)
choose the “Call Me” option, which will instantly dial the phone
number you provide. Should you lose your PIN or registration
confirmation email, simply re-register to receive a new PIN.
A replay of the call will be made accessible online at
https://investor.omeros.com/archived-events.
About Omeros Corporation
Omeros is an innovative biopharmaceutical company committed to
discovering, developing and commercializing small-molecule and
protein therapeutics for large-market and orphan indications
targeting immunologic disorders including complement-mediated
diseases, cancers, and addictive and compulsive disorders. Omeros’
lead MASP-2 inhibitor narsoplimab targets the lectin pathway of
complement and is the subject of a biologics license application
(BLA) pending before FDA for the treatment of hematopoietic stem
cell transplant-associated thrombotic microangiopathy (HSCT-TMA).
Omeros’ long-acting MASP-2 inhibitor OMS1029 is currently in a
Phase 1 clinical trial. OMS906, Omeros’ inhibitor of MASP-3, the
key activator of the alternative pathway of complement, is
advancing in clinical programs for paroxysmal nocturnal
hemoglobinuria (PNH), complement 3 (C3) glomerulopathy. Funded by
the National Institute on Drug Abuse, Omeros’ lead
phosphodiesterase 7 (PDE7) inhibitor OMS527 is in clinical
development for the treatment of cocaine use disorder (CUD) and is
also being developed as a therapeutic for other addictions as well
as for a major complication of treatment for movement disorders.
Omeros also is advancing a broad portfolio of novel immuno-oncology
programs comprised of two cellular and three molecular platforms.
For more information about Omeros and its programs, visit
www.omeros.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240327216351/en/
Jennifer Cook Williams Cook Williams Communications, Inc.
Investor and Media Relations IR@omeros.com
Omeros (NASDAQ:OMER)
Gráfico Histórico do Ativo
De Out 2024 até Out 2024
Omeros (NASDAQ:OMER)
Gráfico Histórico do Ativo
De Out 2023 até Out 2024